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Objectives. β2-adrenergic agonists, such as clenbuterol, have been shown to promote the hypertrophy of healthy skeletal muscles
and to ameliorate muscle wasting in a few pathological conditions in both animals and humans. We intended to investigate the
clinical eﬃcacy of clenbuterol on attenuating denervation-induced muscle atrophy. Methods. A double-blind, placebo-controlled,
parallel, and randomized trial was employed. 71 patients, suﬀering from brachial plexus injuries, were given either clenbuterol
(60μg, bid) or placebo for 3 months. Before and at the end of the study, patients were given physical examinations, biopsies
of biceps brachii, electromyograms (EMGs), and other laboratory tests. Results. Compared with placebo treatment, clenbuterol
signiﬁcantlymitigatedthedecreasesincross-sectionalareasoftypeIandIImuscleﬁbersandalleviatedthereductioninﬁbrillation
potential amplitudes, without any adverse eﬀects. Conclusions. Clenbuterol safely ameliorated denervated muscle atrophy in this
cohort; thus larger clinical studies are encouraged for this or other β2 agonists on denervation-induced muscle atrophy.
1.Introduction
Selective beta-2 adrenergic agonists have been shown to
increase skeletal muscle mass and function under physiolog-
ical conditions in a variety of species. This is attributable to
their roles in controlling protein synthesis and degradation,
via Gαs and Gβγ coupled signalings and Ca2+/ubiquitin-
dependent pathways, respectively [1]. β2 agonists also ame-
liorate animal muscle wasting in denervation, amyotrophic
lateral sclerosis, muscular dystrophy, disuse, aging, and
myocardial unloading models [2–8].
In patients with immobilization conditions or muscular
dystrophy, β2 agonists, such as clenbuterol, increase lean
body mass and enhance skeletal muscle functions [9–11]. In
addition, clenbuterol (up to 720μg/day) promotes myocar-
dial recovery in patients with myocardial unloading atrophy
resulting from applications of left ventricular assist devices
[12–14].
In comparison with other β2 agonists, clenbuterol, a
long-acting and functionally selective agent, is the most
eﬀective drug in preventing muscle wasting, with the least
adverse eﬀects [13, 15–18]. However, the clinical eﬃcacy of
clenbuterol on denervated muscle atrophy has not yet been
reported; denervation-induced muscle atrophy remains an
unmet medical need. Also muscle atrophy status ultimately
determines the functional recovery of repaired peripheral
nerve injuries [19]. Based on β2 agonists’ roles in promoting
hypertrophy of intact skeletal and cardiac muscles, and in
preventing muscle wasting in preclinical studies, we hypoth-
esized that clenbuterol may mitigate denervated muscle atro-
phy in humans. The current pilot trial tested clenbuterol’s
eﬀects on retarding denervation-induced muscle atrophy in
patients.
2.MaterialsandMethods
2.1. Patients. 71 patients were recruited to this study at
the Hand Surgery Department of Huashan Hospital, Fudan
University in Shanghai. Entering criteria: (1) patients had2 ISRN Pharmaceutics
loss of innervation in the biceps brachii for more than one
month,anddiagnosiswasachievedthroughthecombination
of history, physical examinations, electromyogram (EMG),
and examinations during surgeries. (2) The loss of inner-
vation must have resulted solely from traumatic injuries
to the brachial plexus, namely, C5/6, C5/6/7, or C5-T1
injuries, and not from other causes, such as virus infections
or autoimmune diseases. (3) Besides the trial, all studied
patientshadphrenicnervestransferredtomusculocutaneous
nerves, in addition to various other nerve transfers. (4) All
patients were routinely given oral Vitamin B6 (10mg tid)
and Dibazolum (10mg tid) to facilitate nerve regeneration
during the trial period. (5) The participating patients
had no central nervous system injuries or other diseases
and were not in any other trials. (6) All patients signed
the informed consents. Excluding criteria: (1) ischemia or
traumatic compressions occurring directly on the biceps
brachii or musculocutaneous nerves; (2) pregnant or breast
feeding women; (3) patients on β-blockers for other diseases;
(4) patients who had experienced serious adverse events
from other β-agonists before; (5) patients, who were not
strictly compliant in taking trial drugs and completing
the adjunctive therapies as above, were not analyzed; (6)
patients, who did not revisit at their scheduled time, were
not analyzed.
2.2.Design. Patientswererecruitedfrom5therapeuticteams
led by independent investigators at the department. They
were labeled with case numbers and randomly assigned
into clenbuterol or placebo groups. The codes were stored
separately. It was only referred to by the organizer at the end
of the study or when a severe adverse event occurred. Neither
the therapeutic team members nor patients knew which
group a patient was assigned to. The EMG examination
staﬀs and the processor/evaluator of the biopsy samples were
masked from treatment allocations. Clenbuterol was formu-
lated as 60μg/10mL in sealed glass tubes by pharmacists. A
total of 20,000 tubes of clenbuterol or placebo were made,
respectively. Shelf stability at 4◦C was tested to guarantee the
constancy of the active pharmacological ingredient over the
entire study period. Each patient was prescribed 200 tubes of
clenbuterol or placebo and was asked to take the medicine
orally 60μg twice per day for 3 months (∼2μg/kg/day),
without food interference. Signiﬁcant muscle atrophy was
observedduring3-monthperiodafterdenervation[20].And
alsomeaningfulnerveregenerationmayhavenotoccurredin
the majority of cases during the 3-month period, thus it will
not confound the study medicine eﬃcacy. A risk manage-
ment plan was also formed to safeguard the patients. During
hospitalization,patientsinbothgroupsweremonitoreddaily
foranydiscomfortintheﬁrstweekofdrugadministration.It
was planned to stop the treatments if patients demonstrated
eitherallergicresponsesorintolerablemuscletremors,severe
diarrhea, cardiac arrhythmia, or other unexpected adverse
reactions. They were all encouraged to call in to report
any adverse events during the 3-month trial. In addition,
all patients accepted the conventional surgical nerve repairs
as mentioned above. Nevertheless, the patients were not
given any other medicines known to aﬀect muscle atrophy.
Patients in both groups were required for assessments at
3 months after the trial’s initiation. During the follow-up
visit, the leftover drugs were counted to verify compliance,
and a retrospective survey was conducted to ﬁnd out any
potential adverse eﬀects. The study protocol was approved
by the Institutional Review Board at Huashan Hospital. The
planned primary outcome measure was changes in muscle
cross-sectional ﬁber sizes over the treatment period of 3
months, which is a valid and basic method to assess muscle
a t r o p h y .T h es e c o n d a r yo u t c o m em e a s u r e sw e r ec h a n g e si n
ﬁbrillation potential amplitudes and the percentage of biceps
reinnervation after 3 months treatment.
2.3. General Laboratory Evaluations. Before the trial, each
patient was admitted and given a set of laboratory evalu-
ations including a 12-lead electrocardiogram, chest X-ray,
pulmonary function test, and several liver function studies.
Blood urea nitrogen, creatinine, bleeding time, prothrom-
bin time, glucose, calcium, phosphorus, electrolytes, and
complete blood counts with diﬀerentials were also recorded.
By the end of the trial, all patients repeated the above
examinations regardless of their groups.
2.4. EMG Examination. At the commencement and con-
clusion of the trial, each patient was given EMG exam-
inations with a Dantec Neuromatic-2000M (Denmark)
electromyographyinanair-conditionedroom,afteradapting
to a constant temperature for 10 minutes. Patients were
given a full set of conventional EMG examinations on
each nerve of both upper extremities, including sensory
and motor nerve conduction speeds, maximum and evoked
motor unit action potentials (MUAPs), and somatosensory
evokedpotentials(SEPs)atdiﬀerentsegmentsofthebrachial
plexus and terminal branches. The results were compared
between both sides by EMG professionals. If there were any
doubts about the EMG diagnosis, an intraoperational EMG
examination was conducted after exposing the root, trunk,
cord, or some proximal branches of the brachial plexus.
If no MUAP or SEP was detected, ﬁbrillation potential
amplitudes were then recorded, via a concentric needle
electrode inserted perpendicularly into at least three spots
around the midpoints of the biceps brachii. Only the one
with the largest amplitude and biphasic or triphasic shape
was analyzed when several ﬁbrillation ﬁrings were recorded,
because the largest amplitudes best reﬂect the sizes of muscle
ﬁbers closest to the needle tip [20, 21]. The complete EMG
data for the brachial plexus injury diagnosis will not be listed
in the present paper, as those are not as highly relevant as
ﬁbrillation potential amplitudes in the intended trial.
2.5.MuscleBiopsy. All71patientsweregivenmusclebiopsies
at the midpoints of the biceps brachii during nerve repair
operations right before the start of the trial. Biopsy samples
were covered with talc powder and snap frozen in isopentane
precooled in liquid nitrogen. 10μm thick fresh cryostat
sections were made on a cryostat microtome at −20◦Ca n d








Lost to followup (6)
Reinnervation (0)
Poor compliance (15)
Lost to followup (4)
Completed trial by
EMG, n = 15
Completed trial by
EMG, n = 17
Completed trial by
Biopsy, n = 12
Completed trial by
Biopsy, n = 13
Figure 1: Study design and follow-up ﬂow chart.
staining at either pH 4.6 or 9.4 was performed on each
sample to show ﬁber types [22]. Fiber cross-sectional areas
were measured on approximately 300 ﬁbers from three
diﬀerent view ﬁelds with a computed image analysis system;
theaveragewascalculatedforeveryﬁbertypeineachsample.
By the end of the trial, if EMG and physical examinations
showed no signs of reinnervation of the biceps brachii,
patients from both groups were asked to have repetitive
biopsies of the biceps brachii if the patients were fully
compliant to study instructions. The muscle samples were
processed as before.
2.6. Statistical Analysis. All patient information and exam-
inations were put into SPSS software. The changes in
ﬁbrillation potential amplitudes and cross-sectional areas
over the trial period in each patient were used for statistical
analysis. P<0.05 was taken as statistical signiﬁcance.
3. Results
3.1. Characteristics of the Study Subjects. 35 patients were
randomized into clenbuterol group, and 36 patients were
allocated into placebo group. Poor compliance (not taking
medicine as prescribed and delayed followup visit) and
lost to follow-up accounted 19 cases in clenbuteral or
placebo group, respectively. One patient in the clenbuterol
group showed signs of reinnervation of the biceps brachii
(M2) 3 months after the phrenic nerve transfer. This was
determined through physical and EMG examinations. 15
patients in clenbuteral group and 17 patients in the placebo
group completely obeyed the guidelines of the 3-month trial







Figure 2: Representative EMGs prior to (I) and after (III)
clenbuterol treatment, from a 27-year-old male with right brachial
plexus injury for two months at the time of enrollment; (II) and
(IV) are representative EMGs prior to (II) and after (III) placebo
treatment of a 21-year-old male with left brachial plexus injury for
one and a half month before the trial.
and 13 patients in the placebo group accepted repetitive
musclebiopsies.Patientsweremainlyyoungpeoplesuﬀering
from motorcycle accidents or other traumas. There were no
signiﬁcant diﬀerences in ages between the two treatment
groups.Denervationtimebeforetrialenrollmentwasaround
5 months, a period not signiﬁcantly diﬀerent between
the groups (Table 1). All patients accepted similar surgical
procedures and conventional adjunctive therapies. These key
characteristicsmade thepatients in both groups comparable.
3.2. Eﬃcacy on Retarding Muscle Atrophy. Denervated mus-
cles produce spontaneous, repetitive single-ﬁber discharges
that are presented as ﬁbrillation potentials and are detectable
by electromyography. The amplitudes of ﬁbrillation poten-
tials correlate well with muscle ﬁber sizes [20, 21]. Patients
t r e a t e dw i t hc l e n b u t e r o lh a da na v e r a g er e d u c t i o no f5 7μV
in the amplitudes of ﬁbrillation potentials, while patients
accepting the placebo had a 4-time greater decrease over the
same period of time (Table 2, Figure 2).
In the present study, denervated muscle ﬁbers atrophied
over time, and type I ﬁbers had less decrease in cross-
sectional areas than type II, regardless of treatments, similar
to results reported elsewhere [20] .T h er e d u c t i o n so fc r o s s -
sectional areas in type I and II ﬁbers were 413 and 512μm2,
in clenbuterol-treated patients. Yet, those decreases in ﬁber
sizes were correspondingly 66% and 60% greater in placebo-
treated patients (Table 2, Figure 3).
3.3. Adverse Event Monitoring. Out of all the patients, just
one patient felt transient muscle tension 2 days after the
clenbuterol administration. No special intervention was
given except observation and followups; the discomfort
disappeared after attention distraction for half a day. The
electrocardiogram (EKG) of one patient recorded newly
occurring sinus arrhythmia and bradycardia after 3 months4 ISRN Pharmaceutics
Table 1: General characteristics of patients who completed trial.
EMG Biopsy
Clenbuterol Placebo Clenbuterol Placebo
Number 15
M = 13, F = 2
17
M = 14, F = 3
P value 12
M = 11, F = 1
13
M = 12, F = 1
P value
Age, y 27.4 ±1.62 4 .5 ±2.5 >0.05 28.3 ±3.12 7 .3 ±1.6 >0.05
Denervation period before trial, m 4.8 ±0.76 .5 ±1.6 >0.05 4.8 ±1.04 .7 ±0.9 >0.05
Figures are means ± standard errors; y: years, m: months.
Table 2: Changes of ﬁbrillation potential amplitudes and muscle ﬁbers following treatments.
Clenbuterol Placebo
Decrease in cross-sectional areas of type I ﬁbers, μm2 413 ± 91.7 687.1 ± 84.6 P = 0.038
Decrease in cross-sectional areas of type II ﬁbers, μm2 512.1 ± 75.1 821.3 ± 118.7 P = 0.045
Reduction in ﬁbrillation potential amplitude, μV 57.3 ± 32.7 231.5 ± 56.6 P = 0.013
Figures are means ± standard errors.
of clenbuterol administration. He had no discomfort com-
plaints.
Six patients in the clenbuterol group had EKG abnormal-
ities before enrollment, namely, sinus arrhythmia (2 cases),
sinus bradycardia (1 case), incomplete right bundle branch
block (1 case), right ventricular high voltage (1 case), and
counterclockwise rotation of the heart (1 case). They all had
no corresponding symptoms and required no treatments per
consulting with cardiologists. Clenbuterol treatment for 3
months did not change their EKG presences.
Seven patients in the placebo group recorded slight
abnormalities in EKG (4 cases), glucose (2 cases), and
creatinine (1 case) by the end of the study. There were
no abnormalities in lung, liver functions, bleeding time,
prothrombin time, electrolytes, or complete blood counts.
No complaints of muscle tremors, tachycardia, dizziness,
appetite changes, or diarrhea were reported over the trial
period in either group.
4. Discussion
I nt h ep r e s e n ts t u d y ,w ew e r ea b l et or e c r u i tas p e c i a lc o h o r t
of patients in their twenties. This helped to minimize the
eﬀects of aging on muscle atrophy and eliminate this poten-
tial confounding factor in the study, because spontaneous
denervation occurs with aging [23, 24]. All patients had
traumatic brachial plexus injuries with similar postinjury
periods. Muscle ﬁber sizes decrease lineally over time during
the ﬁrst year [20]. In this trial, patients were observed
mainly from the third to eighth month, the period of rapid
atrophy. This time window might have facilitated disclosing
clenbuterol’s eﬃcacy. Also, only one identical muscle of
complete denervation was investigated in all of the patients,
thus eliminating the diﬀerences in muscle ﬁber components
concomitant with studying various or partially innervated
muscles. Such similarities rendered the two groups to
be comparable. The abundant patient population resulted
mainly from motorcycle and construction accidents due to
the transition of economic modernization in China.
This is the ﬁrst clinical study showing that clenbuterol at
120μg/day attenuated denervation-induced muscle atrophy
in humans. It is reported that clenbuterol, at incremental
doses from 120 to 720μg/day over 12 weeks, increases the
mass and strength of the healthy skeletal muscles in man [13,
14].Animalstudiesshowthatdenervatedskeletalmusclesare
20 times more sensitive to clenbuterol than healthy muscles
and the heart [25]. Therefore, 120μg/day of clenbuterol is
believed to be a reasonably high dosage for the denervated
muscles of patients. In the present study, the changes of
ﬁber sizes and ﬁbrillation potentials were used to evaluate
the eﬃcacy, aiding the avoidance of confounding factors
resulting from variations in basal levels between individuals.
Hence, it seems that fewer patients were required to reach a
conclusionthanthenumberneededbyastudylimitedtojust
comparing endpoints.
In animal and large population studies, ﬁbrillation
potential amplitudes reﬂect ﬁber sizes of denervated muscles
[20, 21, 26]. It was noted that clenbuterol treatment alle-
viated the reduction of ﬁbrillation potential amplitudes by
300%, while atrophy of ﬁber sizes was only retarded by 66%
or 60% in type I or II ﬁbers, respectively. This discrepancy
may be due to the fact that diﬀerent muscle ﬁbers were
checked, particularly as muscle ﬁber sizes vary signiﬁcantly
even in one single biopsy sample of a denervated muscle
(Figure 3). Only the largest ﬁbrillation potential amplitudes
were analyzed in this study, which probably originated from
the large muscle ﬁbers. Biopsies tended to collect a small
bundle of muscle ﬁbers, which reﬂects the overall status
of muscle atrophy and should therefore be served as a
gold standard. However, ﬁbrillation potentials seem more
sensitive in detecting the eﬃcacy of therapeutics, which may
consequently be used as an interim surrogate marker for
future studies.
Reinnervation of muscle ﬁbers, such as via axon regen-
eration following surgical repairs, often halts muscle atrophy
and restores muscle functions [27]. Understanding such, we
removed the patient with partial reinnervation of the biceps
brachii from muscle atrophy analysis, to avoid interferenceISRN Pharmaceutics 5
(a) (b)
(c) (d)
Figure 3: Representative images of ATPase staining at pH 9.4 to show darkly stained type II ﬁbers on biopsied biceps brachii (100x
magniﬁcation). (a) is from a 26-year-old male with right brachial plexus injury for 3 months, and (c) is from the same patient after 3-
month clenbuterol treatment. (b) is from another 26-year-old male with right brachial plexus injury for 3 months, and (d) is from the same
patient after 3-month placebo treatment.
with drug eﬀects. Since the distance of nerve regeneration
varies in patients with diﬀerent limb lengths, we could not
determine whether the case of reinnervation was due to
clenbuterol treatment. Though, recent animal studies show
that clenbuterol promotes peripheral nerve regeneration
and prevents neuron loss in pathological conditions, via
upregulating nerve growth factor, basic ﬁbroblast growth
factor and transforming growth factor-β1[ 5, 28, 29]. We
could not conclude if clenbuterol promotes nerve regener-
ation given the short observation period. To explode this,
future studies could stratify patients by the demanding
length of regeneration and by lengthening the treatment and
observation time.
Skeletal muscle contains all three β-adrenoceptor sub-
types(β1,β2 andβ3),withabouta10-foldgreaterproportion
of the β2-adrenoceptor isoform than β1 or β3 receptors
[30, 31]. The expression of subtype receptors remains to
be checked under denervation condition in the future
studies. Conversely, cardiac muscle contains approximately
more than twofold of β1-adrenoceptors than β2[ 1]. This
forms a theoretic basis for adjusting doses of β2 agonists
to aﬀect skeletal rather than myocardial muscles. Indeed,
proper dosages of β2 agonists, such as clenbuterol, separate
the eﬀects on diﬀerent types of muscles in patients [9–
11]. Among the known β2 agonists, clenbuterol appears
to have the safest cardiac proﬁle. To elaborate, clenbuterol6 ISRN Pharmaceutics
given at 1000μg/kg/day, caused no myocardial hypertrophy
in rats, but rather skeletal muscle hypertrophy [32]. Even
though extremely high dose of clenbuterol (2000μg/kg/day)
in animals can induce cardiac hypertrophy, that is still
physiological in its functions, structure, and gene expres-
sions, it is ultimately free of pathological changes [8, 17,
33]. Consistently, clenbuterol (up to 720μg/day) promotes
cardiac recovery in patients with left ventricular unloading
atrophy [12–14].
Physiological dose of clenbuterol in rats, 10μg/kg/day,
attenuated denervated muscle atrophy without aﬀecting
the heart or causing myocyte death [25, 34]. That dosage
was calculated based on the metabolic body weight that
10μg/kg/day in rats is equivalent to 1μg/kg/day in humans,
a dose safely used in asthma treatments [25, 35]. The dose in
the current study was 120μg/day (∼2μg/kg/day for a 60kg
person). It was well tolerated and not associated with any
obvious discomfort, except for one patient with transient
nervousness.Thenewlyoccurringsinusbradycardiaafterthe
clenbuterol trial seemed not be relevant to the activation
of the β1/2 agonist, which usually leads to tachycardia.
Moreover, clenbuterol at the present dose did not exacerbate
preexisting minor EKG abnormalities. This is consistent with
previous reports that the eﬀects of clenbuterol on the heart
are observable at a dose of up to 2100μg/day in combination
therapy for patients using left ventricular assist device. Even
atthosedoses,nosevereadverseeﬀectswereencounteredbut
tremorsandmusclecramps[12,13].Inourstudy,noadverse
eﬀects on liver, kidneys, lungs or hematopoietic system were
observed after the 3-month intake of clenbuterol.
This pilot single-center study was small in scale. The
eﬃcacy would be more apparent in a larger patient popu-
lation with either gradual increments of clenbuterol doses,
or an on and oﬀ schedule to avoid the occurrence of
receptor desensitization. Recent animal studies also show
that clenbuterol is neuroprotective and promotes axon
regeneration [5, 28, 29]. Thus, in combination with its
antiatrophyfunction,clenbuterolanditskindtrulyrepresent
promising and safe agents for countering nerve injuries.
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